Carvedilol as Single Therapy for Heart Failure With Improved Ejection Fraction: A Randomized Clinical Trial (CATHEDRAL-HF)
- PMID: 40372299
- DOI: 10.1016/j.jchf.2025.02.022
Carvedilol as Single Therapy for Heart Failure With Improved Ejection Fraction: A Randomized Clinical Trial (CATHEDRAL-HF)
Keywords: beta-blocker; carvedilol; drug withdrawal; heart failure with improved ejection fraction; recovered ejection fraction.
Conflict of interest statement
Funding Support and Author Disclosures Dr Bocchi has received consulting fees from Servier, AstraZeneca, and Boehringer Ingelheim; has received subsidized travel/registration fees/hotel fees from Servier; has membership in steering committees from Servier, Novartis, and Boehringer Ingelheim; has received research grant support through the Heart Institute from Jansen, Bayer/Merck, AstraZeneca, Boehringer Ingelheim, Pfizer, Novartis, Cardiol Therapeutics, and Eurofarma; and has received honoraria form Servier, Novartis, AstraZeneca, and Boehringer Ingelheim. Dr Moreira Ayub-Ferreira has received honoraria from Abbott, Novartis, and CSL Vifor. Dr Biselli has received honoraria from Abbott. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous